AIP
IMPL

Ameritas Investment Partners’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Ameritas Investment Partners’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-422
Closed -$3K – 3305
2022
Q1 		$3K Hold
422
– – ﹤0.01% 3034
2021
Q4 		$4K Hold
422
– – ﹤0.01% 3069
2021
Q3 		$5K Hold
422
– – ﹤0.01% 3038
2021
Q2 		$4K Buy
+422
New +$5.04K ﹤0.01% 3016

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Ameritas Investment Partners's IMPL Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q2 2022, closing a stake of 422 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in IMPL in Q2 2021 and held it in 4 quarters. The position peaked at $5K in Q3 2021. 36 funds tracked by Wall St. Rank hold IMPL as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 422 Impel Pharmaceuticals Inc. Common Stock shares in Q2 2022, an estimated $3K.
  • Ameritas Investment Partners first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Ameritas Investment Partners's Impel Pharmaceuticals Inc. Common Stock position peaked at $5K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.